AI-Guided CRISPR Finds New Psoriasis Targets in Keratinocytes

Key Takeaways

• Zhao et al. described the first genome-wide CRISPR study in primary adult human skin cells, generating an IL17RA-focused regulatory map in keratinocytes that the authors framed as relevant to psoriasis biology.
• VirtualCRISPR prioritized underrecognized signals from the keratinocyte screen, and ALOX5 and OXTR emerged as practical drug-development targets linked to zileuton and cligosiban.
• In preclinical validation, zileuton altered keratinocyte inflammatory and proliferative programs in three-dimensional skin cultures, and topical zileuton and cligosiban performed comparably to an injected anti-IL17RA comparator in mice, with cligosiban showing the broadest skin restoration.

An AI-guided CRISPR map of human keratinocytes surfaced OXTR and ALOX5 as unexpected psoriasis targets, and the corresponding topical gels reduced disease severity within five days in a mouse model, as reported by Zhao et al. in Nature Communications. Zhao and colleagues paired genome-scale perturbation data with AI-based prioritization to move from target discovery to compound selection, linking OXTR to cligosiban and ALOX5 to zileuton. The efficacy signal described in the report remained preclinical, limited to experimental skin systems and a mouse psoriasis model.

Psoriasis affects roughly 125 million people worldwide, and many patients with moderate-to-severe disease rely on systemic therapies that can reduce cutaneous inflammation but carry injection burden, broad immune exposure, or both. The investigators framed keratinocytes as a central but underexplored disease compartment because these outer skin cells are where psoriatic pathology begins and where locally acting interventions might be developed. Large-scale CRISPR work in keratinocytes had been impractical because standard chemical delivery methods were toxic to the cells, so the team used a centrifuge-based delivery approach to overcome that barrier.

Using approximately 77,000 guide RNAs, the researchers knocked out roughly 19,000 genes one by one in keratinocytes from two human donors and measured how each perturbation changed IL17RA abundance, producing a genome-wide map of regulators in psoriasis-relevant skin cells. The team then applied VirtualCRISPR to separate strong but underrecognized hits from biology that was already heavily represented in the literature. ALOX5 and OXTR emerged as the prioritized candidates, and the authors noted that OXTR had no established connection to psoriasis or skin inflammation in their framing.

In three-dimensional skin cultures, zileuton was reported to reprogram keratinocyte metabolism and suppress inflammatory and proliferative gene programs without immune cells present, which the authors used to support a keratinocyte-directed effect. In the mouse model, topical zileuton and cligosiban were tested alongside a commonly used injected anti-IL17RA drug and were described as comparable to the injected therapy at one week, with restoration of normal skin thickness and a shift toward anti-inflammatory immune-cell signaling. The source also noted existing human safety experience with zileuton and OXTR antagonists outside psoriasis, but not psoriasis-specific human safety data. The authors interpreted the cligosiban findings as consistent with a role for OXTR blockade in barrier dysfunction rather than as evidence of clinical benefit in people.

Clinician Questions

Which psoriasis targets were prioritized by AI-guided CRISPR screening in human keratinocytes?

VirtualCRISPR prioritized underrecognized hits from a genome-wide CRISPR screen in primary adult human keratinocytes, and ALOX5 and OXTR emerged as practical therapeutic candidates. Zileuton targets ALOX5, and cligosiban inhibits OXTR.

How was IL17RA used in the human keratinocyte CRISPR screen for psoriasis?

The researchers used approximately 77,000 guide RNAs to knock out roughly 19,000 genes one by one in keratinocytes from two human donors, then measured how each knockout changed IL17RA abundance to build a genome-wide map of regulators relevant to psoriasis biology.

What preclinical effects were reported with topical zileuton and cligosiban in psoriasis models?

In a mouse model of psoriasis, topical zileuton and cligosiban reduced disease severity within five days and were described as comparable to a commonly used injected anti-IL17RA drug at one week, with restored skin thickness and a shift toward anti-inflammatory immune-cell signaling. These were preclinical findings, not human trial results.

What did zileuton do in three-dimensional skin cultures relevant to psoriasis?

In three-dimensional skin cultures replicating layered human skin architecture, zileuton was reported to reprogram keratinocyte metabolism and suppress inflammatory and proliferative gene programs without immune cells present, supporting a keratinocyte-directed effect in the source framing.